Citations

Clear

7732 citation(s) found for "Ma, Daniel".

Strong Evidence of a Genetic Determinant for Mammographic Density, a Major Risk Factor for Breast Cancer
Vachon, Celine M. , Sellers, Thomas A. , Cunningham, Julie M. , Hilker, Christopher A., Smalley, Regenia L., Schaid, Daniel J. , Kelemen, Linda E. , Vachon, Celine M. , Carlson, Erin E. , Couch, Fergus J. , Pankratz, V. Shane

Mayo Clinic

Cancer Research | September 5, 2007 | Volume: 67 | Issue: 17 | Pages: 8412-8418

10.1158/0008-5472.can-07-1076 | PMID 17804758 Get It

Abstract Increased mammographic density (MD), the proportion of dense tissue visible on a mammogram, is a strong risk factor for breast cancer, common in the population and clusters in families. We conducted the first genome-wide linkage scan to identify genes influencing MD. DNA was obtained from 889 relatives (756 women, 133 men) from 89 families. Percent MD was estimated on 618 (82%) female family members using a validated computer-assisted thresholding method. The genome-wide scan included 403 microsatellite DNA markers with an average spacing of 9 cM. Fine mapping of a region of chromosome 5p (5p13.1-5p15.1) was done using 21 additional closely spaced DNA markers. Linkage analyses were conducted to quantify the evidence for a gene responsible for MD across the genome. The maximum log odds for linkage (LOD) score from the genome-wide scan was on chromosome 5p (LOD = 2.9, supporting linkage by a factor of 102.9 or 794 to 1) with a 1-LOD interval spanning 28.6 cM. Two suggestive regions for linkage were also identified on chromosome 12 (LOD = 2.6, 1-LOD interval of 14.8 cM; and LOD = 2.5, 1-LOD interval of 17.2 cM). Finer mapping of the region surrounding the maximum LOD on chromosome 5p resulted in stronger and statistically significant evidence for linkage (LOD = 4.2) and a narrowed 1-LOD interval (13.4 cM). The putative locus on chromosome 5p is likely to account for up to 22% of variation in MD. Hence, 1 or more of the 45 candidate genes in this region could explain a large proportion of MD and, potentially, breast cancer. [Cancer Res 2007;67(17):8412–8]
FK506-Binding Protein 52 Phosphorylation: A Potential Mechanism for Regulating Steroid Hormone Receptor Activity
Cox, Marc B. , Schumacher, Felix , Büchner, Johannes , Smith, David F. , Riggs, Daniel L. , Heßling, Martin

Mayo Clinic

Molecular Endocrinology | August 23, 2007 | Volume: 21 | Issue: 12 | Pages: 2956-2967

10.1210/me.2006-0547 | PMID 17717070 Get It

Effect of Slice Thickness and Primary 2D Versus 3D Virtual Dissection on Colorectal Lesion Detection at CT Colonography in 452 Asymptomatic Adults
Johnson, C. Daniel, MacCarty, Robert L., Mandrekar, Jay , Harmsen, William S. , Wilson, Lynn A., Fletcher, Joel G. , Limburg, Paul J.

Mayo Clinic

American Journal of Roentgenology | August 22, 2007 | Volume: 189 | Issue: 3 | Pages: 672-680

10.2214/ajr.07.2354 | PMID 17715116 Get It

End Points in Advanced Colon Cancer Clinical Trials: A Review and Proposal
Allegra, Carmen J. , Blanke, Charles D. , Goldberg, Richard M. , Meropol, Neal J. , Saltz, Leonard B. , Yothers, Greg , Sargent, Daniel J. , Buyse, Marc , Grothey, Axel , Venook, Alan P. , Sargent, Daniel J , Saltz, Leonard , Yothers, Greg

Mayo Clinic

Journal of Clinical Oncology | August 17, 2007 | Volume: 25 | Issue: 24 | Pages: 3572-3575

10.1200/jco.2007.12.1368 | PMID 17704403 Get It

Long-Term Results of RTOG Trial 8911 (USA Intergroup 113): A Random Assignment Trial Comparison of Chemotherapy Followed by Surgery Compared With Surgery Alone for Esophageal Cancer
Kelsen, David P., Winter, Katryn A., Gunderson, Leonard L., Mortimer, Joanne , Estes, Norman, Haller, Daniel G. , Kocha, Walter, Minsky, Bruce D. , Roth, Jack A. , Willett, Christopher G. , Ajani, Jaffer A.

Mayo Clinic

Journal of Clinical Oncology | August 17, 2007 | Volume: 25 | Issue: 24 | Pages: 3719-3725

10.1200/jco.2006.10.4760 | PMID 17704421 Get It

Purpose We update Radiation Therapy Oncology Group trial 8911 (USA Intergroup 113), a comparison of chemotherapy plus surgery versus surgery alone for patients with localized esophageal cancer. The relationship between resection type and between tumor response and outcome were also analyzed. Patients and Methods The chemotherapy group received preoperative cisplatin plus fluorouracil. Outcome based on the type of resection (R0, R1, R2, or no resection) was evaluated. The main end point was overall survival. Disease-free survival, relapse pattern, the influence of postoperative treatment, and the relationship between response to preoperative chemotherapy and outcome were also evaluated. Results Two hundred sixteen patients received preoperative chemotherapy, 227 underwent immediate surgery. Fifty-nine percent of surgery only and 63% of chemotherapy plus surgery patients underwent R0 resections (P = .5137). Patients undergoing less than an R0 resection had an ominous prognosis; 32% of patients with R0 resections were alive and free of disease at 5 years, only 5% of patients undergoing an R1 resection survived for longer than 5 years. The median survival rates for patients with R1, R2, or no resections were not significantly different. While, as initially reported, there was no difference in overall survival for patients receiving perioperative chemotherapy compared with the surgery only group, patients with objective tumor regression after preoperative chemotherapy had improved survival. Conclusion For patients with localized esophageal cancer, whether or not preoperative chemotherapy is administered, only an R0 resection results in substantial long-term survival. Even microscopically positive margins are an ominous prognostic factor. After a R1 resection, postoperative chemoradiotherapy therapy offers the possibility of long-term disease-free survival to a small percentage of patients.
Does Preoperative Topical Antimicrobial Scrub Reduce Positive Surgical Site Culture Rates in Men Undergoing Artificial Urinary Sphincter Placement?
Magera, James S., Inman, Brant A. , Elliott, Daniel S. , Inman, Brant A

Mayo Clinic

Journal of Urology | August 15, 2007 | Volume: 178 | Issue: 4 | Pages: 1328-1332

10.1016/j.juro.2007.05.146 | PMID 17698144 Get It

Impact of Complete Response to Chemotherapy on Overall Survival in Advanced Colorectal Cancer: Results From Intergroup N9741
Dy, Grace K. , Krook, James E., Sargent, Daniel J. , Delaunoit, Thierry , Morton, Roscoe F., Fuchs, Charles S. , Ramanathan, Ramesh K., Williamson, Stephen K. , Findlay, B., Pockaj, Barbara A. , Pitot, Henry C., Goldberg, Richard M. , Green, Erin M. , Sticca, Robert P. , Alberts, Steven R. , Sargent, Daniel J , Williamson, Stephen

Mayo Clinic

Journal of Clinical Oncology | August 8, 2007 | Volume: 25 | Issue: 23 | Pages: 3469-3474

10.1200/jco.2007.10.7128 | PMID 17687151 Get It

Purpose To evaluate clinical characteristics and survival outcomes among patients with locally advanced or metastatic colorectal cancer who achieve a complete response (CR) to systemic treatment either alone or with multimodality approach. Patients and Methods Data were collected retrospectively from CRC patients enrolled onto the phase III trial N9741, a National Cancer Institute–funded and Gastrointestinal Cancer Intergroup–sponsored study coordinated by the North Central Cancer Treatment Group. Patients were randomly assigned to combinations of oxaliplatin, fluorouracil (FU)/leucovorin (LV) and irinotecan. The three treatment arms consist of IFL (irinotecan + FU/LV), FOLFOX4 (oxaliplatin + FU/LV), and IROX (irinotecan + oxaliplatin). Median follow-up was 42.6 months. Results Sixty-two (4%) of 1,508 patients had a CR to chemotherapy alone, and an additional 32 (2%) had a CR after multimodality treatment. Factors associated with achieving CR with systemic chemotherapy alone included FOLFOX4 treatment, patients with assessable disease, or a single site of metastasis. Continuing protocol treatment beyond two cycles after documentation of CR was not associated with improved survival. The rate of curative intent resection was significantly higher for patients treated with oxaliplatin-containing regimens (P = .02). Median survival was similar between patients with CR after chemotherapy alone (44.3 months) or after multimodality approach (47.4 months; P = .81). Conclusion FOLFOX4 was more likely to produce a CR than were IFL or IROX. Oxaliplatin regimens were more likely to result in successful surgical resections. Patients who have CR to systemic chemotherapy alone can achieve impressive survival outcomes similar to those seen among patients who attained a CR status after multimodality treatment.
A high-density SNP genome-wide linkage search of 206 families identifies susceptibility loci for chronic lymphocytic leukemia
Sellick, Gabrielle S., Goldin, Lynn R. , Wild, Ruth, Ressenti, Laura, Strom, Sara S., Dyer, Martin J.S. , Mauro, Francesca Romana , Marti, Gerald E., Fuller, Stephen J. , Lyttelton, M. P. A., Keating, Michael J. , Call, Timothy G. , Catovsky, Daniel , Caporaso, Neil E., Houlston, Richard S. , Slager, Susan L. , Kipps, Thomas J. , Mauro, Francesca R , Houlston, Richard S

Mayo Clinic

Blood | August 8, 2007 | Volume: 110 | Issue: 9 | Pages: 3326-3333

10.1182/blood-2007-05-091561 | PMID 17687107 Get It

Abstract Chronic lymphocytic leukemia (CLL) and other B-cell lymphoproliferative disorders display familial aggregation. To identify a susceptibility gene for CLL, we assembled families from the major European (ICLLC) and American (GEC) consortia to conduct a genome-wide linkage analysis of 101 new CLL pedigrees using a high-density single nucleotide polymorphism (SNP) array and combined the results with data from our previously reported analysis of 105 families. Here, we report on the combined analysis of the 206 families. Multipoint linkage analyses were undertaken using both nonparametric (model-free) and parametric (model-based) methods. After the removal of high linkage disequilibrium SNPs, we obtained a maximum nonparametric linkage (NPL) score of 3.02 (P = .001) on chromosome 2q21.2. The same genomic position also yielded the highest multipoint heterogeneity LOD (HLOD) score under a common recessive model of disease susceptibility (HLOD = 3.11; P = 7.7 × 10−5), which was significant at the genome-wide level. In addition, 2 other chromosomal positions, 6p22.1 (corresponding to the major histocompatibility locus) and 18q21.1, displayed HLOD scores higher than 2.1 (P < .002). None of the regions coincided with areas of common chromosomal abnormalities frequently observed in CLL. These findings provide direct evidence for Mendelian predisposition to CLL and evidence for the location of disease loci.
Sound Footing or Slippery Slope? The Value of Secondary Analyses of Randomized Trials
Sargent, Daniel J. , Grothey, Axel , Sargent, Daniel J

Mayo Clinic

Journal of Clinical Oncology | July 30, 2007 | Volume: 25 | Issue: 22 | Pages: 3191-3193

10.1200/jco.2007.11.5089 | PMID 17664465 Get It

Control of Her-2 Tumor Immunity and Thyroid Autoimmunity by MHC and Regulatory T Cells
Jacob, Jennifer B. , Kong, Yi-chi M., Meroueh, Chady , Snower, Daniel P., David, Chella S., Ho, Ye-Shih, Wei, Wei‐Zen , Meroueh, Chady

Mayo Clinic

Cancer Research | July 17, 2007 | Volume: 67 | Issue: 14 | Pages: 7020-7027

10.1158/0008-5472.can-06-4755 | PMID 17638915 Get It

Abstract Immune reactivity to self-antigens in both cancer and autoimmune diseases can be enhanced by systemic immune modulation, posing a challenge in cancer immunotherapy. To distinguish the genetic and immune regulation of tumor immunity versus autoimmunity, immune responses to human ErbB-2 (Her-2) and mouse thyroglobulin (mTg) were tested in transgenic mice expressing Her-2 that is overexpressed in several cancers, and HLA-DRB1*0301 (DR3) that is associated with susceptibility to several human autoimmune diseases, as well as experimental autoimmune thyroiditis (EAT). To induce Her-2 response, mice were electrovaccinated with pE2TM and pGM-CSF encoding the extracellular and transmembrane domains of Her-2 and the murine granulocyte macrophage colony-stimulating factor, respectively. To induce EAT, mice received mTg i.v. with or without lipopolysaccharide. Depletion of regulatory T cells (Treg) with anti-CD25 monoclonal antibody enhanced immune reactivity to Her-2 as well as mTg, showing control of both Her-2 and mTg responses by Treg. When immunized with, Her-2xDR3 and B6xDR3 mice expressing H2bxDR3 haplotype developed more profound mTg response and thyroid pathology than Her-2 or B6 mice that expressed the EAT-resistant H2b haplotype. In Her-2xDR3 mice, the response to mTg was further amplified when mice were also immunized with pE2TM and pGM-CSF. On the contrary, Her-2 reactivity was comparable whether mice expressed DR3 or not. Therefore, induction of Her-2 immunity was independent of DR3 but development of EAT was dictated by this allele, whereas Tregs control the responses to both self-antigens. These results warrant close monitoring of autoimmunity during cancer immunotherapy, particularly in patients with susceptible MHC class II alleles. [Cancer Res 2007;67(14):7020–7]